Recently, the retinoblastoma protein interacting zinc ®nger gene RIZ has been proposed as a candidate for the tumor suppressor locus on 1p36, because of the common loss of RIZ1 RNA in human tumors. In addition, frameshift mutations of this gene have been demonstrated in a variety of tumors with microsatellite instability. Since alterations in this region have been described in malignant melanomas, we investigated DNA of paran-embedded sections from 16 typical naevi, 19 atypical naevi, 33 primary melanoma lesions and 25 metastases and DNA from four melanoma cell lines by PCR and direct sequencing analysis of RIZ. Frameshift mutations in the RIZ gene were found in 17% of melanoma samples and 8.6% of naevi, but we could not demonstrate any missense mutations in the exons of RIZ1. No LOH of the RIZ gene nor any microsatellite instability in six dinucleotide markers or in the mononucleotide repeats IGRIIR, hMSH3, and hMSH6 could be demonstrated in the samples with RIZ frameshift mutations. Although our results do not explain the high rate of deletions in 1p36 found in this tumor, they assign RIZ a potential role in the multi-step tumor forming process of malignant melanoma of the skin.
Introduction
The short arm of chromosome 1, especially the region 1p36, is deleted or rearranged in many human cancers including neuroblastoma, breast cancer and malignant melanoma of the skin (Heim and Mitelman, 1995) . A deletion in 1p36 in malignant melanoma has been shown by a variety of techniques including cytogenetic analysis (Thompson et al., 1995) , loss of heterozygosity (LOH) analysis (Dracopoli et al., 1989; BoÈ ni et al., 1998) and¯uorescence in situ hybridization analysis (FISH) (Poetsch et al., 1998 (Poetsch et al., , 1999 . These data indicate that the region 1p36 may harbor one or more tumor suppressor genes with relevance in malignant melanoma. A possible candidate for such a tumor suppressor gene may be the retinoblastoma protein-interacting zinc ®nger gene RIZ which belongs to the PR domain family (Liu et al., 1997) . Members of this PR domain family are expressed in an unusual yin-yang fashion with two products diering in the presence or absence of the PR domain. The PR + product is underexpressed in cancer cells, whereas the PR 7 product is present or overexpressed. In case of RIZ, a loss of RIZ1 (PR + product) expression has been shown for example in hepatocellular carcinoma, breast cancer and neuroblastoma (He et al., 1998; . Since RIZ1 can induce G2/M cell cycle arrest and apoptosis in breast cancer and hepatocellular carcinoma cell lines, it has been supposed as a candidate tumor suppressor gene (He et al., 1998; Jiang and Huang, 2000) . Recently, RIZ has been shown to demonstrate a high rate of frameshift mutations in colorectal, gastrointestinal, and endometrial cancer (Chadwick et al., 2000; Piao et al., 2000; Sakurada et al., 2001) and forced expression of RIZ1 in colorectal xenograft tumors with RIZ1 mutations resulted in cells undergoing apoptosis (Jiang and Huang, 2001 ). Therefore, we determined the percentage of frameshift mutations and searched for point mutations in the exons of RIZ1 by direct sequencing analysis of 35 typical and atypical naevi and 58 malignant melanoma lesions which ± with two exceptions (case No. NM3 and MM4) ± have been previously analysed by FISH for deletions in 1p36 (Poetsch et al., 1999) . Frameshift positive cases were also investigated for other microsatellite instability with non-coding dinucleotide repeats and coding mononucleotide repeats.
Results

Frameshift mutations of RIZ
Only frameshift mutations in the (A) 9 track could be detected in our melanoma samples (Figure 1 ), but not in the investigated cell lines. They were found in seven metastases of six patients (28%), in two nodular melanoma lesions (11%), in one super®cial spreading melanoma lesion (7%), in two atypical naevi (15%) and in one typical naevus (5%) ( Table 1 ). All but one of these tumor samples had a 1-bp deletion, all of them heterozygous. The exception is one metastatic melanoma lesion (M41) which displayed a 2-bp deletion in the (A) 9 track.
Sequencing analysis of RIZ1
Only two point mutations were found in the sequencing analysis of the exons of RIZ1. First, a G?C change at position 361 could be detected in a part of the cells from the cell line DX3 resulting in an alanine to proline exchange in codon 121. Second, a C?T change at position exons 6 ± 10 (intron 5) could be found in a metastatic melanoma displaying no frameshift mutations (Figure 2 ). This mutation was not found in two other metastases from the same patient which were also investigated.
LOH analysis of RIZ
Of the 49 patients analysed 26 were informative for the studied polymorphism. Only in two cases (one nodular melanoma and one super®cial spreading melanoma) loss of heterozygosity could be demonstrated (data not shown).
Microsatellite instability analysis
We could not detect any microsatellite instability with the microsatellite markers D2S123, D3S1611, D5S107, D17S787, D18S34 or D18S58 in our analysed melanoma samples. In addition, no frameshift mutations were found in the analysed repetitive mononucleotide tracts of IGFIIR, hMSH3, and hMSH6 (data not shown).
Discussion
The retinoblastoma protein-interacting zinc ®nger gene RIZ is one candidate for the tumor suppressor gene locus in the terminal region of chromosome 1 which is often deleted in malignant melanoma of the skin (Dracopoli et al., 1989; Poetsch et al., 1998 Poetsch et al., , 1999 . Due to the yin-yang nature of this gene, changes in the structure of RIZ1 are to be expected for a tumor promoting eect. The frameshift mutation in the (A) 9 tract of exon 8 is expected to cause a truncated RIZ protein lacking part of the C-terminal region involved in the PR binding function. Therefore, we investigated super®cial spreading melanoma, nodular melanoma and metastatic melanoma as well as atypical and typical naevi for changes in the RIZ gene and loss of heterozygosity of this gene.
At the moment we are unable to determine the importance of the two point mutations in RIZ1 found in this study. The missense mutation in exon 5 in one cell line concerns the PR domain thus it may disturb protein function. However, this mutation occurred only in a part of the cells and no other mutations could be found in any cell line. The C?T change in intron 5 in a metastatic melanoma may disturb the splicing of exon 6. Since only archived paran-embedded material up to 10 years old was available for our analysis, we were not able to investigate possible changes of the mRNA.
The occurrence of frameshift mutations in the (A) 9 tract of exon 8 in two SSM, two NM and six metastases prompted us to investigate three other repetitive mononucleotide tracts (IGFIIR, hMSH3, hMSH6) and six dinucleotide markers in these patients and melanoma lesions looking for additional microsatellite instability (MSI) events. We did not ®nd any frameshift mutations in the mononucleotide repeats which is in line with results from other studies (Richetta et al., 2001) . Alterations at dinucleotide repeats have been reported in malignant melanoma, but only in 2 ± 30% of primary melanoma lesions (Richetta et al., 2001; Talwalkar et al., 1998). There- Figure 1 Sequence pro®le of the A (9) tract in malignant melanomas. Examples of frameshift mutations in comparison to the wildtype (above). NM46 (center) has a 1-bp deletion (heterozygous) and MM41 (below) has a 2-bp deletion (heterozygous)
Oncogene Frameshift mutations of RIZ in malignant melanoma M Poetsch et al fore, the absence of changes in the dinucleotide markers tested here is explainable by the small number of lesions investigated. In gastrointestinal and endometrial carcinomas, MSI has been an important other criterion in lesions with RIZ frameshift mutations Chadwick et al., 2000) . Therefore, there are two possible reasons for the occurrence of frameshift mutations in our melanoma samples. First, the alterations could have been developed by chance. This is supported by the fact that in two patients with frameshift mutations we could analyse two or more metastases, but the mutations were restricted to one of the metastases. In addition, we could not correlate our previous FISH results concerning deletions in 1p36 in malignant melanoma (Poetsch et al., 1998 (Poetsch et al., , 1999 with the occurrence of the frameshift mutations in this study. We found deletions in 1p36 only in nodular melanoma lesions or in metastases, but not in super®cial spreading melanoma lesions, whereas two SSM displayed a frameshift mutation. All mutations here manifest themselves heterozygous, which is veri®ed by the fact that no LOH of the RIZ gene could be detected. In contrast, the same nodular and metastatic melanoma samples displayed a deletion in 1p36 as determined by FISH. Therefore, the described deletion in our tumor samples did not stretch over the RIZ gene. In addition, a correlation of our results with survival or recurrence did not reveal any connections.
Second, the RIZ gene could be the one of very few targets of inactivation by MSI pathways in malignant melanoma. Loss of DNA-mismatch repair gene expression has already been demonstrated in melanoma lesions (Korabiowska et al., 1999; Hussein et al., 2001) and in other tumors MSI is strongly associated with a diminished expression of hMLH1, one of the DNA mismatch repair genes (Fleisher et al., 2000) . In melanoma, however, ®rst studies could not correlate MSI in microsatellite markers especially from chromosome 1p and 9p with reduction of hMLH1, hMSH2 of hMSH6 protein expression (Hussein et al., 2001) . Since the authors of this study did not investigate the status of the RIZ gene, it may well be altered in their melanoma lesions with decreased mismatch repair protein expression. Whether the RIZ frameshift mutations in our melanoma lesions re¯ect a defect in DNA mismatch repair genes is still to be determined. Further studies are necessary to elucidate the correlation between the RIZ gene and the DNA mismatch repair genes.
Nevertheless, since tumorigenesis is assumed to be a multistep process in which many mutations lead in the end to the formation of a tumor and since the percentage of frameshift mutations was higher in metastases, alterations in RIZ may be important in the progression of a subset of malignant melanoma of the skin. Further studies including expression analysis of RIZ1 and RIZ2 to evaluate the potential role of this candidate tumor suppressor gene in melanoma are in preparation. In addition, since deletions in 1p36 are a characteristic of this tumor (Dracopoli et al., 1989; Poetsch et al., 1998 Poetsch et al., , 1999 and could not be explained by alterations of the RIZ gene, the existence of other tumor suppressor genes in 1p36 with a greater impact in malignant melanoma of the skin is highly probable.
Materials and methods
Tumors and patients
Fifty-eight non-selected malignant melanoma lesions comprising 14 super®cial spreading melanoma lesions (SSM), 19 nodular malignant melanoma lesions (NM) and 25 metastatic melanoma lesions comprising a wide range of thickness (Breslow index) and Clark levels which were staged and classi®ed as stated elsewhere (Poetsch et al., 1998) were studied. The samples belonged to 49 patients, whose corresponding blood samples or normal tissues were also investigated. Histologic diagnosis of malignant melanoma was documented for all cases. All specimens underwent additional independent histopathologic review (C Woenckhaus). In addition, 16 typical and 19 atypical naevi and the four melanoma cell lines M19, DX3 (Albino et al., 1981) , Indicating deletions in 1p36 in a prior FISH study (Poetsch et al., 1998 (Poetsch et al., , 1999 ; n.d. ± not determined; c DOD, died of disease, NED, no evidence of disease; AWD, alive with disease; LTF, lost to follow-up Frameshift mutations of RIZ in malignant melanoma M Poetsch et al MEWO (Siracky et al., 1982) , and LT5.1 have been included in this study.
DNA isolation from peripheral blood and paraffin embedded tissue
DNA isolation from peripheral blood was performed with the Blood Extraction Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. DNA isolation from paran embedded tissue was done as previously described (Poetsch et al., 2001) . Brie¯y, hematoxylin eosin stained slides were carefully inspected by light microscopy to identify areas which carry a sucient amount (at least 3 mm 2 ) of tumor tissue measured by a scaled optical adjustment. This same area was then identi®ed on the unstained 10 mm dewaxed, rehydrated and airdried tissue section which was ®xed in an optical installation allowing the isolation of tumor tissue without adherent non-neoplastic structures under microscopical control. The High Pure PCR Template Preparation Kit (Roche Molecular Biochemicals, Mannheim, Germany) was used for the DNA extraction.
PCR and sequencing analysis of RIZ
The following PCR conditions were used: 100 ng template DNA were ampli®ed in a 25 ml reaction volume containing 200 mM dNTPs, 2 mM MgCl 2 , 15 mM Tris/HCl, 50 mM KCl, 0.3 mM primers, and 1 Unit AmpliTaq Gold (Applied Biosystems, Weiterstadt, Germany) by denaturing at 958C for 10 min, followed by 30 cycles of 958C for 30 s, 52 ± 608C for 90 s, 728C for 120 s, and additional 30 min at 728C with the Trio Thermocycler (Biometra, GoÈ ttingen, Germany). Detection of the frameshift mutations was done with the primers described by Piao et al. (2000) and the sequencing of each exon was performed with primers as published by Fang et al. (2000) . For the sequencing PCR the BigDye Ready Reaction Kit from Applied Biosystems was used with the same primers as above according to the manufacturer's instructions with the following PCR conditions: 25 cycles of 958C for 30 s, 608C for 4 min. The PCR products were sequenced with the ABI 310 DNA sequencer (Applied Biosystems). Each mutation was veri®ed by a second sequencing reaction of an independent ampli®cation product.
Assessment of LOH
The RIZ Pro704 deletion polymorphism was assayed by PCR and analysed by electrophoresis on denaturing gel as described by Fang et al. (2000) .
Microsatellite assay
We studied six dinucleotide microsatellite markers located on chromosome 2 (D2S123), chromosome 3 (D3S1611), chromosome 5 (D5S107), chromosome 17 (D17S787), and chromosome 18 (D18S34 and D18S58) in those nine patients and 10 tumor samples with frameshift mutations and in additional ®ve matched patient/tumor samples as controls. Primer sequences were obtained from the Genome Data Base (http://gdbwww.gdb.org). The PCR was performed in two multiplex analyses each comprising three dierent labeled primers in a ®nal volume of 12.5 ml containing 50 ± 80 ng DNA, 0.3 mM of each primer, 200 mM of each dNTP, 1.5 mM MgCl 2 , 15 mM Tris/HCl, 50 mM KCl, and 1 Unit AmpliTaq Gold (Applied Biosystems, Weiterstadt, Germany) by denaturing at 958C for 10 min, followed by 35 cycles of 958C for 30 s, 558C for 90 s, 728C for 120 s, and additional 10 min at 728C with the Trio Thermocycler (Biometra, GoÈ ttingen, Germany). 1.5 ml PCR product was mixed with 12 ml deionized formamide and 0.5 ml ROX-labeled internal lane standard, denatured at 908C for 120 s, snap-cooled on ice and electrophoresed with the ABI 310 DNA sequencer (Applied Biosystems).
Frameshift mutation analysis of IGFIIR, hMSH3, and hMSH6
We searched for frameshift mutations in the coding mononucleotide repeats IGRIIR(G) 8 , hMSH3(A) 8 , and hMSH6(C) 8 by PCR and direct sequencing analysis. Primer sequences and PCR conditions were as described by Catasus et al. (2000) . Sequencing was done as described above. N Hibberts for providing the cell line M19. We thank S Seefeldt and M Maschke for excellent technical assistance.
